=Eyegate Pharmaceuticals (EYEG) announces top-line results for trial of EGP-437 in cataract surgery

Eyegate Pharmaceuticals announces top-line results for trial of EGP-437 in cataract surgery 
"The efficacy results for the absence of inflammatory cells in the EGP-437 treatment group met our expectations, but the vehicle group response was better than anticipated. The magnitude of reduction for EGP-437 compares favorably with the historical data from studies of other anti-inflammatory products, which we believe is an encouraging sign," said Randall Olson MD, strategic advisor to EyeGate. The double-masked, randomized, vehicle-controlled Phase 2b study enrolled 106 subjects at seven U.S. clinical sites. The trial evaluated the safety and efficacy of trans-scleral iontophoretically-delivered EGP-437, dexamethasone, through the Company's EyeGate II Delivery System in patients that have previously undergone cataract surgery with implantation of a monofocal posterior chamber IOL, starting immediately after surgery.